Titlebook: Kidney Cancer; Robert A. Figlin Book 2003 Kluwer Academic Publishers 2003 Staging.cancer.carcinoma.cell.genetics.kidney.minimally invasive

calumniate

感情

按等级

Cancer Treatment and Researchhttp://image.papertrans.cn/k/image/542675.jpg

STANT

978-1-4613-5083-5Kluwer Academic Publishers 2003

cogitate

Kidney Cancer978-1-4615-0451-1Series ISSN 0927-3042 Series E-ISSN 2509-8497

Conducive

口诀法

The Role of Systemic Chemotherapy in the Treatment of Kidney Cancerpproximately 10 months with a 3-year survival rate of about 10%.. RCC is typically described as chemotherapy (and radiation therapy) resistant. Most authors agree that biologic response modifiers (i e immunotherapy) represent standard first-line treatment for advanced RCC.

Thyroxine

Monoclonal Antibody Therapy of Kidney Cancer once RCC has metastasized, treatment options are very limited. This tumor is not radiosensitive, resistant to chemotherapy, and treatment with biological response modifiers (IL-2, IFN) leads to low response rates.

微生物

https://doi.org/10.1007/978-1-4615-0451-1Staging; cancer; carcinoma; cell; genetics; kidney; minimally invasive surgery; molecular genetics; preventi

Salivary-Gland